MONTREAL, Nov. 6, 2024 /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in four prominent healthcare investor conferences over the coming weeks, providing critical updates on its advancements in precision medicine.
Stifel Healthcare Conference 2024
- Format: Presentation and one-on-one investor meetings
- Date: Monday, November 18, 2024, from 1:50 p.m. to 2:20 p.m. ET
- Location: Lotte New York Palace Hotel, New York, NY
At the Stifel Healthcare Conference, Thryv Therapeutics will present key updates on its precision medicine approach, targeting novel treatments for Long QT Syndrome, heart failure and atrial fibrillation. Thryv’s management team will also be available for one-on-one meetings throughout the day on Monday, November 18. To arrange a meeting, please contact admin@thryvtrx.com.
Jefferies London Healthcare Conference 2024
- Dates: November 19-21, 2024
- Location: London, UK
To arrange a meeting at Jefferies, please contact admin@thryvtrx.com.
Piper Sandler 36th Annual Healthcare Conference
- Format: One-on-one investor meetings
- Dates: December 3-5, 2024
- Location: New York, NY
To arrange a meeting at Piper Sandler, please contact admin@thryvtrx.com.
Wells Fargo Virtual Private Biotech Symposium
- Format: One-on-one investor meetings
- Date: December 12, 2024
To arrange a virtual meeting, please contact admin@thryvtrx.com.
About Thryv Therapeutics Inc.
Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) to treat Long QT Syndrome, heart failure and atrial fibrillation. For more information, please visit www.thryvtrx.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/thryv-therapeutics-announces-participation-in-four-major-upcoming-investor-conferences-302297779.html
SOURCE Thryv Therapeutics Inc.
